Key Highlights

  • Modular Medical (NASDAQ:MODD) reported a fiscal second-quarter net loss of USD 7.1 million, or USD 0.90 per share, against USD 7.8 million, or USD 4.21 per share, a year earlier.
  • Selling, general and administrative expenses rose 43.8% to USD 3.2 million, while Research and Development fell 29.8% to USD 3.9 million.
  • Cash stood at USD 5.1 million on September 30, 2026, after USD 12.3 million was used in operations over six months and USD 11.2 million was raised in financing.
  • The filing says the company has no Revenue to cover operating costs and flags substantial doubt about its ability to continue as a going concern.

Smaller Loss Masks a Shift From Research to Sales

Modular Medical (NASDAQ:MODD) filed its Quarterly Report on November 16, 2026, for the second quarter of its fiscal 2027, which ended September 30, 2026. The company is a commercial-stage medical device Business developing a two-part patch insulin pump, called MODD1, which received FDA clearance in September 2024. The quarterly net loss was USD 7,103 thousand against USD 7,790 thousand, a decline of about 8.8% on a calculated basis, and the six-month loss was USD 13,589 thousand against USD 14,492 thousand. The per-share loss fell sharply because of a 1-for-30 Reverse Stock Split completed in March 2026, which reduced the share count.

Consulting Costs Push Selling Expenses Up 43.8%

Selling, general and administrative expenses reached USD 3,215 thousand against USD 2,236 thousand, and USD 5,382 thousand for six months, up 37.8%. The report ties the increase mainly to about USD 1.2 million of added consulting fees for outsourced sales and marketing, plus Investor relations and Capital Markets advisory work. Research and development spending fell to USD 3,926 thousand from USD 5,593 thousand, with lower personnel, materials, consulting and Stock Compensation costs. Research headcount dropped to 39 from 56 a year earlier, and sales and administrative headcount slipped to 10 from 13. Management expects research costs to hold steady or rise modestly in the second half and sales costs to increase.

Going Concern Doubt Follows Registered Offering and ATM Sales

Cash was USD 5.1 million and the accumulated Deficit USD 126.6 million. Operating Activities used about USD 12.3 million over six months, against USD 10.8 million a year earlier, while financing brought in about USD 11.2 million from a registered direct offering and sales under a 2026 at-the-market program. The company says it has no revenue to cover operating expenses and that its survival depends on raising more capital through Equity or debt. Management also disclosed a material weakness tied to accounting for a commercialization services contract, after costs incurred in the period had been recorded as prepaid expenses. Purchase orders for machinery and supplies totaled roughly USD 1.5 million, and 9,736,909 shares were outstanding as of November 12, 2026.

Where Things Stand

Modular Medical (NASDAQ:MODD) is still warning of Going Concern doubt because it has no revenue yet, a USD 7.1 million quarterly loss and USD 5.1 million of cash against about USD 12.3 million used in operations over six months. The smaller loss reflects lower research spending, partly offset by heavier outsourced sales and Marketing costs. The points to watch are the next capital raise, any early commercial traction for MODD1, the remediation of the identified control weakness and whether sales spending keeps climbing as management expects.